EcoDrugPlus

Angiotensin Ii Receptor Type 2

Ensembl ID : ENSEEEG00000001973
Gene Symbol: AGTR2
2 Cross references
171 Possible Orthologues:

Angiotensin Ii Receptor, Type 2

Ensembl ID : ENSEEEG00000002332
Gene Symbol: AGTR2
1 Cross references
145 Possible Orthologues:

Apelin Receptor 2

Ensembl ID : ENSEEEG00000013581
Gene Symbol: APLNR2
4 Cross references
172 Possible Orthologues:

Arachidonate 12-Lipoxygenase

Ensembl ID : ENSEEEG00000011730
Gene Symbol: ALOX12
4 Cross references
200 Possible Orthologues:

Arachidonate 5-Lipoxygenase A

Ensembl ID : ENSEEEG00000008660
Gene Symbol: ALOX5A
4 Cross references
213 Possible Orthologues:

Arachidonate 5-Lipoxygenase-Activating Protein

Ensembl ID : ENSEEEG00000002496
Gene Symbol: ALOX5AP
4 Cross references
201 Possible Orthologues:

Arginine Vasopressin Receptor 1a

Ensembl ID : ENSEEEG00000019388
Gene Symbol: AVPR1A
4 Cross references
189 Possible Orthologues:

Arginine Vasopressin Receptor 1ab

Ensembl ID : ENSEEEG00000004475
Gene Symbol: AVPR1AB
4 Cross references
135 Possible Orthologues:

Arginine Vasopressin Receptor 2

Ensembl ID : ENSEEEG00000017725
Gene Symbol: AVPR2
4 Cross references
197 Possible Orthologues:

Arginine Vasopressin Receptor 2

Ensembl ID : ENSEEEG00000024039
Gene Symbol: AVPR2
2 Cross references
197 Possible Orthologues:

Aromatase

Ensembl ID : ENSEEEG00000015657
Gene Symbol: LOC113577298
4 Cross references
255 Possible Orthologues:

Atrial Natriuretic Peptide Receptor 2

Ensembl ID : ENSEEEG00000010123
Gene Symbol: LOC113588239
3 Cross references
186 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).